The treatment of RA is aimed at either the systemic suppression of inflammation via the use of glucocorticosteroids, nonsteroidal anti-inflammatory drugs, cytostatics that block white-blood-cell division, or at the targeted inhibition of molecular inflammatory targets—TNF-α, IL-6, IL-12, and JAK—with the use of monoclonal antibodies and JAK kinase inhibitors [3,4,5]. Here, IL6 is linked to rheumatoid arthritis.